 The purpose of this study is to determine the recommended dose of the combination therapy of sorafenib with hepatic arterial infusion of low dose cisplatin and fluorouracil on patients with advanced hepatocellular carcinoma Phase I, and to evaluate the efficacy of this combination therapy in the recommended dose Phase II. 